Safety and Effectiveness of an Anti-HIV Drug Combination With and Without Hydroxyurea in Patients With Early HIV Infection
HIV Infections
About this trial
This is an interventional treatment trial for HIV Infections focused on measuring Prospective Studies, HIV-1, Didanosine, Drug Therapy, Combination, Stavudine, HIV Protease Inhibitors, Hydroxyurea, Ritonavir, Indinavir, Reverse Transcriptase Inhibitors, Anti-HIV Agents, Viral Load, Reverse Transcriptase Polymerase Chain Reaction
Eligibility Criteria
Inclusion Criteria Patient may be eligible if they: Are in the early stages of HIV infection. Are at least 13 years old (consent of parent or guardian required if under 18). Agree to use 2 barrier methods of birth control (such as condoms) during the study and for 3 months after. Exclusion Criteria Patients will not be eligible if they: Have a liver or kidney problem (Group I only). Have a history of pancreatitis (Group I only). Have ever taken anti-HIV drugs before. Plan to take anti-HIV drugs other than the study drugs during the study. (Study drugs may be substituted if the investigator finds it necessary.) Have had radiation treatment within 30 days prior to study entry. Have received chemotherapy or any experimental therapy within 30 days of study entry or plan to receive such therapies during the study. Have taken interferons, interleukins, colony-stimulating factors, and HIV vaccines within 30 days prior to study entry. Have taken certain other drugs. Are pregnant or breast-feeding.